综合性转录水平分析显示,在阿尔茨海默氏病的进展过程中,转录重编程发生
Hao Wu1, Jiao Wang1, Xiaoyuan Hu2
1Laboratory of Molecular Neural Biology, School of Life Sciences, Shanghai University, Shanghai, China.
Frontiers in aging neuroscience
|July 3, 2023
概括
这项研究揭示了早期和晚期阿尔茨海默病 (AD) 中明显的转录基因变化. 了解这些替代拼接事件为早期AD诊断和向治疗提供了新的途径.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 中度和高级AD阶段之间的关键差异仍然不清楚.
- 转录组分析提供了疾病进展的高分辨率视图.
研究的目的:
- 在无症状AD (AsymAD) 和转录水平的AD中对转录组失调进行比较分析.
- 识别和描述AD进展中的替代拼接事件 (ASE) 和异形切换.
- 在AD中探索RNA结合蛋白 (RBP) 介导的调节网络.
主要方法:
- 在454个与AD相关的样本 (145个对照,140个AsymAD,169个AD) 上进行了转录分辨率分析.
- 确定了差异拼接的替代拼接事件 (ASE) 和异形切换事件.
- 构建的RNA结合蛋白 (RBP) -ASE调控网络.
主要成果:
- 在AsymAD中确定了4,056个ASEs,在AD中确定了1,200个ASEs.
- 在AsymAD中揭示了287个异型切换事件,在AD中揭示了222个.
- 观察到对特定基因的差异性转录使用,如APOA2,突出显示AD.的异形特异性变化.
结论:
- 提供了对ASYMAD和AD的转录组干扰的转录分辨率见解.
- 这些发现可能有助于发现AD的早期诊断生物标志物.
- 结果支持对阿兹海默症患者开发新的治疗策略.
相关概念视频
Alzheimer's Disease: Overview
527
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527
Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220


